Navigation Links
Weitz & Luxenberg Files Seroquel Diabetes Lawsuit Against AstraZeneca
Date:6/19/2008

AstraZeneca's CEO to be Deposed in London on Friday, June 20, 2008

NEW YORK, June 19 /PRNewswire/ -- Weitz & Luxenberg, PC, one of the leading plaintiffs' litigation law firms in America, filed a lawsuit today against pharmaceutical giant AstraZeneca on behalf of a New York City Fire Department Emergency Medical Technician whose diabetes was allegedly caused by AstraZeneca's drug Seroquel. The plaintiff, EMT Ernest Armstead, was one of the many brave responders on the morning of September 11, 2001. He was severely injured when the World Trade Center's North Tower collapsed as he was helping victims at the foot of the buildings.

Suffering from Post-Traumatic Stress Disorder after recovery from his 9/11 physical injuries, Mr. Armstead was prescribed Seroquel, which Weitz & Luxenberg claims did not carry a warning that the powerful drug can cause diabetes. He thereafter developed the debilitating, life-long disease known as Type 2 diabetes. Mr. Armstead joins thousands of others across the country who has filed actions claiming that Seroquel caused them to develop diabetes and that AstraZeneca hid its knowledge of this risk from the FDA, doctors and patients.

In a letter dated November 16, 2006, the Department of Health and Human Services of the Food and Drug Administration cited violations of the Federal Food, Drug, and Cosmetic Act in connection with AstraZeneca's use of promotional material deemed by the FDA to be "false or misleading because it minimizes the risk of hyperglycemia and diabetes mellitus" and which "raises significant public health and safety concerns through its minimization of the risks associated with Seroquel."

A deposition of AstraZeneca's Chief Executive Officer, David Brennan, about his company's alleged undisclosed knowledge regarding the dangerous side effect of diabetes, is being taken this Friday, June 20th in London, England at the law offices of Baker Botts, a U.S. firm defending the company. Lawyers from three of the lead plaintiffs' counsel in the litigation (Blizzard, McCarthy & Nabers; Weitz & Luxenberg; and Bailey, Perrin, Bailey) will be conducting the deposition.

About Weitz & Luxenberg P.C.: Weitz & Luxenberg, founded in 1986, is one of the leading plaintiffs' litigation law firms in America. The firm has played leading roles in national and local litigations involving asbestos/mesothelioma, DES, silicone breast implants, defective medicines and medical devices, and general negligence, among others. A forerunner in the legal fight against environmental polluters, Weitz & Luxenberg has worked with clients harmed by MTBE among other toxins. The firm recently secured a landmark MTBE settlement against some of the country's biggest oil companies, which have agreed to pay $423 million in a suit involving the contamination of 153 public water systems nationally.


'/>"/>
SOURCE Weitz & Luxenberg, PC
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Genzyme Files Applications for Approval of Mozobil in the United States and Europe
2. Jazz Pharmaceuticals Files Form S-3 Registration Statements
3. Cephalon Files Patent Infringement Lawsuit Against Watson Pharmaceuticals
4. Catalyst Pharmaceutical Partners, Inc. Files Form S-3 Shelf Registration Statement
5. Immunosyn Corporation Files 10-Q
6. Vaxgen Files 10-Q for First Quarter With SEC, Provides Future Burn Rate Guidance
7. Benda Pharmaceutical Files Amendment To Form S-1
8. Oncothyreon files investigational new drug application for PX-866 oncology compound
9. Vion Pharmaceuticals Files Plan With Nasdaq
10. NeoGenomics Files Annual Report on Form 10-KSB with the SEC
11. Codexis, Inc. Files Registration Statement for Proposed Initial Public Offering
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... , June 23, 2016   Boston ... of novel compounds designed to target cancer stemness ... has been granted Orphan Drug Designation from the ... treatment of gastric cancer, including gastroesophageal junction (GEJ) ... inhibitor designed to inhibit cancer stemness pathways by ...
(Date:6/23/2016)... , June 23, 2016  The Prostate Cancer Foundation (PCF) is ... treatments and faster cures for prostate cancer. Members of the Class of 2016 ... countries. Read More About the Class of 2016 PCF ... ... ...
(Date:6/23/2016)... NC (PRWEB) , ... June 23, 2016 , ... In ... University Hospital in Denmark detail how a patient who developed lymphedema after being treated ... tissue. The results could change the paradigm for dealing with this debilitating, frequent side ...
(Date:6/23/2016)... ... June 23, 2016 , ... ClinCapture, the only free ... and will showcase its product’s latest features from June 26 to June 30, ... poster on Disrupting Clinical Trials in The Cloud during the conference. DIA ...
Breaking Biology Technology:
(Date:6/22/2016)... American College of Medical Genetics and Genomics was once again ... of the fastest-growing trade shows during the Fastest 50 Awards ... Las Vegas . Winners are ... of the following categories: net square feet of paid exhibit ... 2015 ACMG Annual Meeting was ranked 23 out of 50 ...
(Date:6/16/2016)... FRANCISCO , June 16, 2016 ... size is expected to reach USD 1.83 ... by Grand View Research, Inc. Technological proliferation and ... banking applications are expected to drive the market ... ) , The development of advanced ...
(Date:6/3/2016)... 3, 2016 Das ... Nepal hat ein 44 ... geprägter Kennzeichen, einschließlich Personalisierung, Registrierung und IT-Infrastruktur, ... Produktion und Implementierung von Identitätsmanagementlösungen. Zahlreiche renommierte ... Januar teilgenommen, aber Decatur wurde als konformste ...
Breaking Biology News(10 mins):